Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose Densified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk (aaIPI at least 2) Diffuse Large B-Cell Lymphoma.

Next Previous
Trial Profile

Dose Densified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk (aaIPI at least 2) Diffuse Large B-Cell Lymphoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Methotrexate; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHIC

Most Recent Events

  • 02 Mar 2020 Status changed from active, no longer recruiting to completed.
  • 06 Nov 2019 Results (n=96) of two clinical studies: a phase 2 trial; dose-dense chemoimmunotherapy (NCT01502982) and a early systemic CNS prophylaxis with high-dose methotrexate (CHIC or NCT01325194), assessing clinical feasibility and prognostic value of ctDNA in prospectively collected samples from high risk B-cell lymphoma patients, released in 61st Annual Meeting and Exposition of the American Society of Hematology
  • 04 Sep 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top